Androgen Insensitive Disease

• Intermittent Chemotherapy - When Is Enough Enough? (May 2008)
• Chemotherapy - Updated Survival Data from TAX 327 Study: Docetaxel Plus Prednisone Versus Mitoxanthrone Plus Prednisone for Advanced Prostate Cancer. (JCO January 10, 2008) (March 2008)
• Latest Report Of 'Accent': Docetaxel And Calcitriol (October 2006)
• Intermittent Chemotherapy in Metastatic Prostate Cancer (June 2006)
• PSADT Predicts Survival In Hormone Refractory Prostate Cancer (August 2005)
• Chemotherapy For Hormone Refractory Prostate Cancer: The Context and the New Content (April 2005)
• Duration Of Survival Of Patients Who Developed Hormone Refractory Prostate Cancer (August 2004)
• Intermittent Chemotherapy for Chemotherapy Responders - An Early Trial (August 2003)
• Neoadjuvant chemotherapy for "high risk" prostate cancer - ready for prime time? (June 2003)
• Report of an encouraging outcome of a trial combining "Taxotere" with Vitamin D (1,25-dihydroxyvitamin D3) (February 2003)
• MSKCC nomogram predicts survival for patients who fail androgen ablation therapy (November 2002)
• Protocols for combining "Taxotere" with antisense agents inhibiting bc12 and cluster in gene expression. (January 2003)

« Back to topic index